Terns Pharmaceuticals stock hits 52-week low at $4

In a challenging year for Terns Pharmaceuticals Inc., the company’s stock has touched a 52-week low, dipping to $4, despite maintaining a strong balance sheet with more cash than debt and a robust current ratio of 32.99. This latest price level reflects a significant downturn for the biopharmaceutical firm, which has seen its shares plummet by 49.05% over the past year, though six analysts have recently revised their earnings estimates upward with price targets ranging from $7.50 to $34. Investors have been closely monitoring Terns Pharmaceuticals as it navigates through a period marked by volatility in the biotech sector, with the company’s stock typically moving counter to broader market trends with a beta of -0.36. The 52-week low serves as a critical indicator for shareholders and potential investors, signaling a period of reassessment and potential opportunity for those looking at the long-term prospects of the company. According to InvestingPro analysis, the stock appears undervalued, with additional insights available in the comprehensive Pro Research Report, including 8 more key ProTips for informed decision-making.

In other recent news, Terns Pharmaceuticals has announced the departure of their Chief Financial Officer, Mark Vignola, effective February 1, 2025. Following his resignation, Vignola will continue to provide services as an independent contractor through a consulting agreement until July 31, 2025. Meanwhile, Amy Burroughs, the company’s CEO, has been appointed as the interim principal financial officer, and David Strauss will serve as the interim principal accounting officer. On the financial analysis front, Oppenheimer has maintained an Outperform rating for Terns Pharmaceuticals, raising the price target to $20.00, highlighting the promising data from the Phase 1 CARDINAL study of TERN-701 for Chronic Myeloid Leukemia (CML). The study has shown encouraging safety and efficacy outcomes, with a cumulative major molecular response rate of 50% among patients treated for three months or more. The analysts emphasized the potential advantages of TERN-701 over existing treatments, noting improved tolerability and significant reductions in BCR-ABL1 transcripts. Additionally, Terns Pharmaceuticals plans to initiate a Phase 2 study for TERN-601, a treatment for obese or overweight adults, in early 2025. These developments underscore the company’s ongoing efforts in advancing its drug pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.